지혈 밸브 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Hemostasis Valve Market Size, Share & Trends Analysis Report By Type (Hemostasis Valve Y- Connectors, Double Y- Connector Hemostasis Valves), By Application (Angiography, Angioplasty), By End Use, By Region and Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,632,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,083,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,985,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

지혈 밸브 시장 규모와 동향 :

세계 지혈 밸브 시장 규모는 2024년에 1억 8,460만 달러를 달성했으며, 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 5.8%로 성장할 것으로 예측됩니다.

심혈관 질환의 유병률 증가, 지지적인 규제 프레임워크, 노인 인구 증가, 기술의 진보가 시장 성장을 크게 촉진하고 있습니다. World Heart Report 2024는 대기 오염이 모든 주요 심혈관 질환(CVD)을 악화시킨다고 강조합니다. 2019년에는 주변 대기 오염과 관련된 420만 명의 사망자 중 70% 가까이가 심혈관 문제, 특히 허혈성 심장 질환(190만 명 사망)과 뇌졸중(90만 명 사망) 때문이었습니다. 이 때문에 혈관조영이나 혈관성형술과 같은 진단·치료 수술 수요가 높아지고 있으며, 지혈 밸브는 카테터 치료 중에 혈류를 제어하여 환자의 안전을 확보하기 위해 필수적입니다.

낮은 침습 절차에 대한 선호도 증가도 시장 성장을 뒷받침하는 중요한 요소입니다. 낮은 침습 절차는 기존의 개복 수술에 비해 통증 완화, 입원 기간 단축, 회복 시간 단축, 합병증 위험 감소 등 수많은 이점을 제공합니다. 그 결과, 이러한 절차를 용이하게 하는 의료기기에 대한 수요가 높아지고 있습니다. 지혈 밸브는 혈류를 정확하게 제어하고 수술 중 누출을 방지하기 위해 낮은 침습 카테터를 사용한 인터벤션에 필수적입니다. 2024년 6월, Journal of the Society for Cardiovascular Angiography &Interventions에 게재된 논문에서는 경대퇴경 카테터 대동맥판 치환술(TAVR) 시의 지혈이 통상 봉합사를 통한 혈관 폐쇄 장치(VCD)를 이용한 프리클로저법으로 달성된다고 논의되었습니다. 최근에는 지혈이 실패한 경우 외장 제거 후 콜라겐 플러그 VCD를 통합하는 하이브리드 접근법이 도입되었습니다.

세계의 인구동태는 출생률의 감소와 건강 관리의 진보로 인한 평균 수명의 연장으로 고령화로 현저하게 변화하고 있습니다. 세계보건기구(WHO)에 따르면 60세 이상 인구는 2050년까지 두배로 늘어나 세계에서 약 21억 명에 달할 것으로 예상됩니다. 이 인구 역학의 변화는 노인에서 심혈관 질환(CVD)을 포함한 노화 관련 질병의 유병률 증가를 강조합니다. 미국 심장협회가 2023년 11월에 발표한 논문에 따르면, 심부전은 광범위하고 다면적인 심혈관계 질환이며, 670만명 이상의 미국인에게 영향을 미치며, 특히 65세 이상의 노인들 사이에서 유행하고 있습니다. 심혈관계 질환에 걸리기 쉬운 고령화 사회는 진단·치료 수술 수요를 촉진해, 시장 성장을 견인하고 있습니다.

의료기기의 기술적 진보는 시장 성장을 가속하는데 매우 중요합니다. 재료, 설계 및 기능의 혁신으로 보다 효과적이고 신뢰할 수 있는 지혈 밸브가 개발되었습니다. 예를 들어 고급 폴리머와 코팅을 사용하면 이러한 장치의 내구성과 생체 적합성이 향상되고 혈전증과 감염과 같은 합병증이 감소합니다. 게다가 사용하기 쉬운 락 기구나 강화된 씰링 능력 등의 새로운 기능을 도입하는 것으로, 임상 현장에 있어서의 지혈 밸브의 효율이 향상하고 있습니다. 예를 들어, 보스턴 사이언티픽의 WATCHDOG 지혈 밸브는 누설을 최소화하는 혁신적인 크로스 슬릿 설계를 채택하여 여러 장치를 동시에 수용할 수 있는 8층 루멘을 갖추고 있습니다. 또한, 수술 중 편안함을 높이기 위해 고안된 엄지 받침 기능도 제공합니다. 이러한 설계 요소는 전체적으로 출혈과 공기 색전증의 위험을 줄이는 데 기여하며 의료 개입 전반에 걸쳐 환자의 안전을 최우선으로 생각합니다. 이러한 기술적 개선은 절차가 보다 안전하고 효율적으로 되고, 지혈 밸브의 채용을 촉진합니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 지혈 밸브 시장 : 변동 요인·경향·범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 지혈 밸브 시장 : 분석 도구
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석
  • 파이프라인 분석

제4장 지혈 밸브 시장 : 유형별 추정과 동향 분석

• 세계의 지혈 밸브 시장 : 유형별 대시보드
• 세계의 지혈 밸브 시장 : 유형별 변동 분석
• 세계의 지혈 밸브 시장 : 유형별(수익 베이스)
• 지혈 밸브 Y자 커넥터
• 이중 Y자 커넥터 지혈 밸브
• 한손 조작식 지혈 밸브
• 기타

제5장 지혈 밸브 시장 : 용도별 추정과 동향 분석

• 세계의 지혈 밸브 시장 : 용도별 대시보드
• 세계의 지혈 밸브 시장 : 용도별 변동 분석
• 세계의 지혈 밸브 시장 : 용도별(수익 베이스)
• 혈관조영술
• 혈관성형술

제6장 지혈 밸브 시장 : 최종용별 추정 및 동향 분석

• 세계의 지혈 밸브 시장 : 최종 용도별 대시보드
• 세계의 지혈 밸브 시장 : 최종 용도별 변동 분석
• 세계의 지혈 밸브 시장 : 최종 용도별(수익 베이스)
• 병원
• 외래수술센터(ASC)
• 기타

제7장 지혈 밸브 시장 : 지역별 추정과 동향 분석(국가별, 유형별, 용도별, 최종 용도별)

• 지역별 대시보드
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 최신 동향과 영향 분석 : 주요 제조업체별
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 유통업체·채널 파트너 목록
  • 주요 고객
  • 주요 기업의 시장 점유율 분석(2024년)
• 기업 프로파일
  • Boston Scientific Corporation
  • Teleflex Incorporated
  • Merit Medical Systems
  • B. Braun SE
  • Terumo Corporation
  • Abbott
  • Argon Medical Devices
  • Freudenberg Medical
  • SCW Medicath Ltd
  • Lepu Medical Technology(Beijing) Co.,Ltd.
  • Nipro
  • DeRoyal Industries, Inc.
  • Antmed Corporation
  • Beijing Demax Medical Technology Co

KTH

영문 목차

영문목차

Hemostasis Valve Market Size & Trends:

The global hemostasis valve market size was estimated at USD 184.6 million in 2024 and is projected to grow at a CAGR of 5.8% from 2025 to 2030. The increasing prevalence of cardiovascular diseases, supportive regulatory frameworks, rising geriatric population, and technological advancements are significantly driving the market growth. The World Heart Report 2024 highlights that air pollution worsens all major cardiovascular diseases (CVDs). In 2019, nearly 70% of the 4.2 million deaths linked to ambient air pollution were due to cardiovascular issues, particularly ischaemic heart disease (1.9 million deaths) and stroke (900,000 deaths). This, in turn, drives the demand for diagnostic and therapeutic procedures like angiography and angioplasty, where hemostasis valves are essential to ensure patient safety by controlling blood flow during catheterization procedures.

The growing preference for minimally invasive procedures is another significant factor propelling the market growth. Minimally invasive techniques offer numerous benefits over traditional open surgeries, including reduced pain, shorter hospital stays, faster recovery times, and lower risk of complications. As a result, there is a heightened demand for medical devices that facilitate these procedures. Hemostasis valves are integral to minimally invasive catheter-based interventions, as they enable precise control of blood flow and prevent leakage during the procedure. In June 2024, an article in the Journal of the Society for Cardiovascular Angiography & Interventions discussed how hemostasis during transfemoral transcatheter aortic valve replacement (TAVR) is usually achieved with a suture-mediated vascular closure device (VCD) via a preclosure technique. Recently, a hybrid approach has been introduced, incorporating a collagen-plug VCD after sheath removal in cases where hemostasis fails.

The global demographic landscape is undergoing a notable shift towards aging, driven by declining birth rates and advancements in healthcare that have prolonged life expectancy. According to the World Health Organization (WHO), the number of people aged 60 years and older is expected to double by 2050, reaching approximately 2.1 billion globally. This demographic transition underscores the increasing prevalence of age-related conditions, including cardiovascular diseases (CVDs) among older adults. According to the article published by the American Heart Association in November 2023, heart failure is a widespread and multifaceted cardiovascular condition impacting more than 6.7 million Americans, particularly prevalent among individuals aged 65 and older. The aging population is susceptibility to cardiovascular diseases drive the demand for diagnostic and therapeutic procedures, driving the market growth.

Technological advancements in medical devices are pivotal in driving the market growth. Materials, design, and functionality innovations have developed more effective and reliable hemostasis valves. For instance, using advanced polymers and coatings has improved the durability and biocompatibility of these devices, reducing complications such as thrombosis and infection. In addition, incorporating novel features such as easy-to-use locking mechanisms and enhanced sealing capabilities has increased the efficiency of hemostasis valves in clinical settings. For instance, the WATCHDOG Hemostasis Valve by Boston Scientific Corporation incorporates an innovative cross-slit design to minimize leakage, complemented by an 8F inner lumen that simultaneously accommodates multiple devices. In addition, it includes a thumb rest feature designed for enhanced comfort during procedures. The design elements collectively contribute to reducing blood loss and the risk of air embolism, prioritizing patient safety throughout medical interventions. These technological improvements ensure that procedures are safer and more efficient, boosting the adoption of hemostasis valves.

Global Hemostasis Valve Market Report Segmentation

This report forecasts revenue growth at global, regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global hemostasis valve market report based on type, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Hemostasis Valve Y- Connectors
• Double Y- Connector Hemostasis Valves
• One- Handed Hemostasis Valves
• Others
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Angiography
• Angioplasty
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Ambulatory Surgical Centers
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application outlook
  • 2.2.3. End use outlook
• 2.3. Competitive Insights

Chapter 3. Hemostasis Valve Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Growing demand for minimally invasive surgeries
    • 3.2.1.3. Improved healthcare infrastructure
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of hemostasis valves
    • 3.2.2.2. Regulatory hurdles
• 3.3. Hemostasis Valve Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Hemostasis Valve Market: Type Estimates & Trend Analysis

• 4.1. Global Hemostasis Valve Market: Type Dashboard
• 4.2. Global Hemostasis Valve Market: Type Movement Analysis
• 4.3. Global Hemostasis Valve Market by Type, Revenue
• 4.4. Hemostasis Valve Y- Connectors
  • 4.4.1. Hemostasis valve Y- connectors market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Double Y- Connector Hemostasis Valves
  • 4.5.1. Double Y- connector hemostasis valves market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.6. One- Handed Hemostasis Valves
  • 4.6.1. One - handed hemostasis valves market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.7. Others
  • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Hemostasis Valve Market: Application Estimates & Trend Analysis

• 5.1. Global Hemostasis Valve Market: Application Dashboard
• 5.2. Global Hemostasis Valve Market: Application Movement Analysis
• 5.3. Global Hemostasis Valve Market by Application, Revenue
• 5.4. Angiography
  • 5.4.1. Angiography market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Angioplasty
  • 5.5.1. Angioplasty market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Hemostasis Valve Market: End Use Estimates & Trend Analysis

• 6.1. Global Hemostasis Valve Market: End Use Dashboard
• 6.2. Global Hemostasis Valve Market: End Use Movement Analysis
• 6.3. Global Hemostasis Valve Market by End Use, Revenue
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Ambulatory Surgical Centers
  • 6.5.1. Ambulatory surgical centers market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Hemostasis Valve Market: Regional Estimates & Trend Analysis by Country, Type, Application and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Boston Scientific Corporation
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Teleflex Incorporated
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Merit Medical Systems
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. B. Braun SE
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Terumo Corporation
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Abbott
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Argon Medical Devices
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Freudenberg Medical
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. SCW Medicath Ltd
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Lepu Medical Technology (Beijing)Co.,Ltd.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Nipro
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. DeRoyal Industries, Inc.
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives
  • 8.4.13. Antmed Corporation
    • 8.4.13.1. Company overview
    • 8.4.13.2. Financial performance
    • 8.4.13.3. Product benchmarking
    • 8.4.13.4. Strategic initiatives
  • 8.4.14. Beijing Demax Medical Technology Co
    • 8.4.14.1. Company overview
    • 8.4.14.2. Financial performance
    • 8.4.14.3. Product benchmarking
    • 8.4.14.4. Strategic initiatives

관련자료